5-(1-甲基环丙基)-1,3,4-噻二唑-2-胺 | 908269-41-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 5-(1-甲基环丙基)-1,3,4-噻二唑-2-胺
• 英文名称: 5-(1-methylcyclopropyl)-1,3,4-thiadiazol-2-amine
• CAS: 908269-41-0
• 化学式: C₆H₉N₃S
• 分子量: 155.224
• InChiKey: YLCDVSLTWVMHOW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  80
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-(1-甲基环丙基)-1,3,4-噻二唑-2-胺 、 2'-chloro-5'-methoxy-6-methyl-[4,4'-bipyridine]-3-carboxylic acid 在 N,N,N',N'-tetramethylchloroformamidinium hexafluorophosphate 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以9 %的产率得到2'-chloro-5'-methoxy-6-methyl-N-(5-(1-methylcyclopropyl)-1,3,4-thiadiazol-2-yl)-(4,4'-bipyridine)-3-carboxamide
  参考文献：
  名称：

  [EN] THIADIAZOLYL COMPOUNDS AS DNA POLYMERASE THETA INHIBITORS
  [FR] COMPOSÉS THIADIAZOLYLES UTILISÉS COMME INHIBITEURS DE L'ADN POLYMÉRASE THÊTA

  摘要：

  Disclosed herein are certain thiadiazolyl derivatives Formula (I): (I) that inhibit DNA Polymerase Theta (Polθ) activity, in particular inhibit Polθ activity by inhibiting ATP dependent helicase domain activity of Polθ. Also, disclosed are pharmaceutical compositions comprising such compounds and methods of treating and/or preventing diseases treatable by inhibition of Polθ such as cancer, including homologous recombination (HR) deficient cancers.

  公开号：

  WO2023067515A1
• 作为产物：
  描述：

  1-甲基环丙烷-1-羧酸 、 氨基硫脲 在 三氯氧磷 作用下， 以 1,4-二氧六环 为溶剂， 生成 5-(1-甲基环丙基)-1,3,4-噻二唑-2-胺
  参考文献：
  名称：

  [EN] THIADIAZOLYL COMPOUNDS AS DNA POLYMERASE THETA INHIBITORS
  [FR] COMPOSÉS THIADIAZOLYLES UTILISÉS COMME INHIBITEURS DE L'ADN POLYMÉRASE THÊTA

  摘要：

  Disclosed herein are certain thiadiazolyl derivatives Formula (I): (I) that inhibit DNA Polymerase Theta (Polθ) activity, in particular inhibit Polθ activity by inhibiting ATP dependent helicase domain activity of Polθ. Also, disclosed are pharmaceutical compositions comprising such compounds and methods of treating and/or preventing diseases treatable by inhibition of Polθ such as cancer, including homologous recombination (HR) deficient cancers.

  公开号：

  WO2023067515A1

文献信息

• NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS
  申请人：Carroll William A.

  公开号：US20090105306A1

  公开（公告）日：2009-04-23

  The present invention relates compounds of formula (I) wherein A and R 1 are as defined in the specification, pharmaceutical compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and pharmaceutical compositions.

  本发明涉及以下式（I）的化合物 其中A和R1如规范中所定义，包括这些化合物的药物组合物，以及使用这些化合物和药物组合物治疗疾病和疾病的方法。
• COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS
  申请人：Carroll William A.

  公开号：US20100249129A1

  公开（公告）日：2010-09-30

  Disclosed herein are compounds of formula (I) wherein Ring A and R 1 are as defined in the specification. Pharmaceutical compositions comprising such compounds, and methods for treating conditions and disorders using such compounds and pharmaceutical compositions are also disclosed.

  本文揭示了以下式(I)的化合物 其中环A和R 1 如规范中所定义。还披露了包含这些化合物的药物组合物，以及使用这些化合物和药物组合物治疗疾病和疾病的方法。
• IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS VEGF-R2 INHIBITORS
  申请人：Barda David Anthony

  公开号：US20090227622A1

  公开（公告）日：2009-09-10

  The present invention provides compounds that are inhibitors of VEGF-R2 of the formula: (I) and methods of using these compounds.

  本发明提供了公式（I）的VEGF-R2抑制剂化合物以及使用这些化合物的方法。
• Compounds as cannabinoid receptor ligands
  申请人：Carroll William A.

  公开号：US08492371B2

  公开（公告）日：2013-07-23

  Disclosed herein are compounds of formula (I) wherein Ring A and R1 are as defined in the specification. Pharmaceutical compositions comprising such compounds, and methods for treating conditions and disorders using such compounds and pharmaceutical compositions are also disclosed.

  本文披露的是式(I)的化合物，其中环A和R1的定义如说明书所述。本文还披露了包含这些化合物的制药组合物，以及使用这些化合物和制药组合物治疗疾病和疾病的方法。
• Imidazo[1,2-A]pyridine compounds as VEGF-R2 inhibitors
  申请人：Eli Lilly and Company

  公开号：US07666879B2

  公开（公告）日：2010-02-23

  The present invention provides compounds that are inhibitors of VEGF-R2 of the formula: (I) and methods of using these compounds.

  本发明提供了公式为(I)的抑制VEGF-R2的化合物以及使用这些化合物的方法。